日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven Diseases

直接进入III期临床试验:基于模型的方法加速Depemokimab在白细胞介素-5驱动疾病中的临床开发

Zecchin, Chiara; Schalkwijk, Stein; Pouliquen, Isabelle J; Berges, Alienor; Bird, Nicholas; Follows, Richard; Austin, Daren

Extranodal Lymphoplasmacytic Lymphoma Responding Rapidly to Zanubrutinib: A Case Series

结外淋巴浆细胞淋巴瘤对泽布替尼快速反应:病例系列

Brown, Samuel; Rusbridge, Jillian; Follows, George; Santarsieri, Anna

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

在共价布鲁顿酪氨酸激酶抑制剂预处理的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中,Pirtobrutinib 与 Idelalisib/Rituximab 或 Bendamustine/Rituximab 的 III 期试验 (BRUIN CLL-321)

Sharman, Jeff P; Munir, Talha; Grosicki, Sebastian; Roeker, Lindsey E; Burke, John M; Chen, Christine I; Grzasko, Norbert; Follows, George; Mátrai, Zoltán; Sanna, Alessandro; Qiu, Lugui; Feng, Ru; Hua, Vu Minh; Jurczak, Wojciech; Ritgen, Matthias; Yi, Shuhua; Bosch, Francesc; Coombs, Catherine C; Bao, Katherine; Patel, Vishalkumar; Liu, Bin; Compte, Livia; Guntur, Ananya; Wang, Denise Y; Hill, Marisa; Leow, Ching Ching; Ghia, Paolo; Barr, Paul M

The long-term effects of chemotherapy on normal blood cells

化疗对正常血细胞的长期影响

Emily Mitchell # ,My H Pham # ,Anna Clay # ,Rashesh Sanghvi ,Nicholas Williams ,Sandra Pietsch ,Joanne I Hsu ,Nina Friesgaard Øbro ,Hyunchul Jung ,Aditi Vedi ,Sarah Moody ,Jingwei Wang ,Daniel Leonganmornlert ,Michael Spencer Chapman ,Ellie Dunstone ,Anna Santarsieri ,Alex Cagan ,Heather E Machado ,E Joanna Baxter ,George Follows ,Daniel J Hodson ,Ultan McDermott ,Gary J Doherty ,Inigo Martincorena ,Laura Humphreys ,Krishnaa Mahbubani ,Kourosh Saeb Parsy ,Koichi Takahashi ,Margaret A Goodell ,David Kent ,Elisa Laurenti ,Peter J Campbell ,Raheleh Rahbari ,Jyoti Nangalia # ,Michael R Stratton #

Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis

端粒缩短成为衰老造血和白血病发生过程中克隆选择的工具

Matthew A McLoughlin #,Sruthi Cheloor Kovilakam #,William G Dunn #,Muxin Gu,Jake Tobin,Yash Pershad,Nicholas Williams,Daniel Leongamornlert,Kevin Dawson,Laura Bond,Ludovica Marando,Sean Wen,Rachael Wilson,Giampiero Valenzano,Vasiliki Symeonidou,Justyna Rak,Aristi Damaskou,Malgorzata Gozdecka,Xiaoxuan Liu,Clea Barcena,Josep Nomdedeu,Paul Costeas,Ioannis D Dimitriou,Edoardo Fiorillo,Valeria Orrù,Jose Guilherme de Almeida,Thomas McKerrell,Matthew Cullen,Irina Mohorianu,Theodora Foukaneli,Alan J Warren,Chi Wong,George Follows,Anna L Godfrey,Emma Gudgin,Francesco Cucca,Eoin McKinney,E Joanna Baxter,Moritz Gerstung,Jonathan Mitchell,Daniel Wiseman,Alexander G Bick,Margarete Fabre,Pedro M Quiros,Jyoti Nangalia,Siddhartha Kar,George S Vassiliou

Author Correction: The long-term effects of chemotherapy on normal blood cells

作者更正:化疗对正常血细胞的长期影响

Mitchell, Emily; Pham, My H; Clay, Anna; Sanghvi, Rashesh; Williams, Nicholas; Pietsch, Sandra; Hsu, Joanne I; Øbro, Nina Friesgaard; Jung, Hyunchul; Vedi, Aditi; Moody, Sarah; Wang, Jingwei; Leonganmornlert, Daniel; Spencer Chapman, Michael; Dunstone, Ellie; Santarsieri, Anna; Cagan, Alex; Machado, Heather E; Baxter, E Joanna; Follows, George; Hodson, Daniel J; McDermott, Ultan; Doherty, Gary J; Martincorena, Inigo; Humphreys, Laura; Mahbubani, Krishnaa; Saeb Parsy, Kourosh; Takahashi, Koichi; Goodell, Margaret A; Kent, David; Laurenti, Elisa; Campbell, Peter J; Rahbari, Raheleh; Nangalia, Jyoti; Stratton, Michael R

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

在ELEVATE-TN研究的6年随访结果中,阿卡替尼联合奥妥珠单抗治疗与化疗免疫疗法相比,可改善初治慢性淋巴细胞白血病患者的生存期。

Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Patel, Krish; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Hughes, Marie; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Follows, George; Walker, Patricia; Ghia, Paolo; Janssens, Ann; Byrd, John C; Ferrant, Emmanuelle; Ferrajoli, Alessandra; Wierda, William G; Wachira, Catherine Wangui; Suterwala, Batul T; Miranda, Paulo; Munugalavadla, Veerendra; Wun, Chuan-Chuan; Woyach, Jennifer A

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

更正:ELEVATE-TN 研究 4 年随访结果显示,在初治慢性淋巴细胞白血病患者中,阿卡替尼联合或不联合奥妥珠单抗与奥妥珠单抗联合苯丁酸氮芥的疗效和安全性。

Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Pagel, John M; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Corbett, Gillian; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Coutre, Steven; Follows, George; Walker, Patricia; Karlsson, Karin; Ghia, Paolo; Janssens, Ann; Cymbalista, Florence; Woyach, Jennifer A; Ferrant, Emmanuelle; Wierda, William G; Munugalavadla, Veerendra; Yu, Ting; Wang, Min Hui; Byrd, John C

Microbial reaction rate estimation using proteins and proteomes

利用蛋白质和蛋白质组估算微生物反应速率

McCain, J Scott P; Britten, Gregory L; Hackett, Sean R; Follows, Michael J; Li, Gene-Wei

Cumulative review of hypertension in patients with chronic lymphocytic leukemia treated with acalabrutinib

对接受阿卡替尼治疗的慢性淋巴细胞白血病患者高血压的累积性回顾

Ferrajoli, Alessandra; Follows, George; Marmor, Yotvat; Roos, Jack; Bajwa, Naghmana; Madhira, Venkata; Nozaki, Kenji; Miranda, Paulo; Pennap, Dinci; Patel, Krish